

Figure S1 The outcomes of the Egger tests for (A) tumors differentiation; (B) lymph-vascular invasion; (C) perineural invasion; (D) different tumor locations; (E) node status; (F) T stage; (G) CA199; (H) CEA; (I) LMR; (J) cystic stone; (K) jaundice; (L) chemotherapy; (M) radiotherapy; (N) margin status.




Figure S2 The outcomes of the sensitivity analyses for (A) tumors differentiation; (B) lymph-vascular invasion; (C) perineural invasion; (D) different tumor locations; (E) node status; (F) T stage; (G) CA199; (H) CEA; (I) LMR; (J) cystic stone; (K) jaundice; (L) chemotherapy; (M) radiotherapy; (N) margin status.




Figure S3 The outcomes of the subgroup analyses for (A) tumors differentiation (country); (B) tumors differentiation (country); (C) lymph-vascular invasion (country); (D) perineural invasion (country); (E) different tumor locations (year); (F) different tumor

© HepatoBiliary Surgery and Nutrition. All rights reserved.